Sarepta hammered after FDA outlines eteplirsen concerns

Sarepta Therapeutics Inc. (NASDAQ:SRPT) sank $8.69 (44%) to $11.02 on Monday after FDA released a second set of briefing documents expressing concerns about the company's data package for eteplirsen ( AVI-4658) to treat Duchenne muscular dystrophy (DMD) amenable

Read the full 388 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE